Atlas Trials

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Clinical trial NCT03229382 · TERMINATED

Trial details

NCT number
NCT03229382
Sponsor
Polish Lymphoma Research Group
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2018-05-14
Primary completion
2020-01-31
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.